Form 4: Neurocrine Biosciences Chief Regulatory Officer Exercises Options and Sells Shares Under 10b5-1 Plan

Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, exercised stock options and subsequently sold an equal number of shares at a profit under a pre-arranged 10b5-1 trading plan.

Summary

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences Inc. (NBIX), executed a transaction on July 10, 2025.
• Delaet acquired 457 shares of common stock by exercising non-qualified stock options at a price of $79.02 per share.
• Concurrently, Delaet disposed of 457 shares of common stock at a price of $135 per share.
• This disposition was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan, which was adopted by Delaet on November 29, 2023.
• Following these transactions, Delaet's direct beneficial ownership of common stock decreased from an implied 5,187 shares to 4,730 shares.
• The exercised options were granted on January 31, 2022, and vest in 48 equal monthly installments beginning February 28, 2022, with an expiration date of January 31, 2032.
• After the exercise, 2,261 non-qualified stock options remain beneficially owned by Delaet.

Sentiment

Score: 6

Explanation: The transaction involves both an option exercise (positive for the individual, showing value realization) and a sale of shares. The sale was pre-planned under a 10b5-1 plan, which mitigates negative sentiment often associated with insider sales, making it a largely neutral event for the company's stock, leaning slightly positive due to the profitable exercise.

Positives

• The exercise of stock options indicates a realization of value from previously granted equity incentives.
• The sale price of $135 per share is significantly higher than the exercise price of $79.02, indicating a profitable transaction for the insider.

Negatives

• The sale of shares by a Chief Regulatory Officer reduces insider ownership, which some investors might view as a slight negative signal, though mitigated by the pre-planned nature of the sale.

Future Outlook

NA

Industry Context

This transaction is an individual insider's equity activity and does not directly reflect broader industry trends or competitive dynamics. It is a routine compensation-related transaction for a pharmaceutical/biotechnology company executive.

Stakeholder Impact

• Shareholders: The sale of shares by an insider, even if pre-planned, slightly reduces insider ownership, which some investors might view neutrally to slightly negatively. However, the profitable exercise of options demonstrates the value of equity compensation.
• Employees: The transaction highlights the company's equity compensation program, which can be a positive for employee retention and motivation.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Ingrid Delaet, Chief Regulatory Officer, Equity Compensation